Evaluation of the neonatal streptozotocin model of diabetes in rats: Evidence for a model of neuropathic pain
Por:
Barragán-Iglesias P., Oidor-Chan V.H., Loeza-Alcocer E., Pineda-Farias J.B., Velazquez-Lagunas I., Salinas-Abarca A.B., Hong E., Sánchez-Mendoza A., Delgado-Lezama R., Price T.J., Granados-Soto V.
Publicada:
1 ene 2018
Resumen:
Background: The purpose of this study was to evaluate the participation of satellite glial cells (SGC), microglia and astrocytes in a model of streptozotocin-induced diabetes initiated in neonatal rats (nSTZ) and to determine the pharmacological profile for pain relief. Methods: nSTZ was used to induce experimental diabetes. Von Frey filaments were used to assess tactile allodynia. Drugs were given by systemic administration. Western blotting and immunohistochemistry were used to determine protein expression and cellular localization. Results: nSTZ produced mild hyperglycemia, weight loss, glucose intolerance, and reduction of nerve conduction velocity of C fibers. Moreover, nSTZ enhanced activating transcription factor 3 (ATF3) immunoreactivity in dorsal root ganglia (DRG) and sciatic nerve of adult rats. ATF3 was found in SGC (GFAP+ cells) surrounding DRG at week 16. Late changes in ATF3 immunoreactivity in DRG correlated with up-regulation of ATF3 and GFAP protein expression. nSTZ increased GFAP and OX-42 immunoreactivity and percentage of hypertrophied and ameboid microglia in the spinal dorsal horn. These changes correlated with the presence of mechanical hypersensitivity (tactile allodynia). Administration of gabapentin (30–100 mg/kg, po) and metformin (200 mg/kg/day, po for 2 weeks) alleviated tactile allodynia, whereas morphine (1–3 mg/kg, ip) had a modest effect. Conclusions: Results suggest that nSTZ leads to activation of SGC, microglia and astrocytes in DRG and spinal cord. Pharmacological profile in the nSTZ model resembles diabetic neuropathic pain in humans. Our findings support the conclusion that the nSTZ rat model has utility for the study of a long-lasting diabetic neuropathic pain. © 2017 Institute of Pharmacology, Polish Academy of Sciences
Filiaciones:
Barragán-Iglesias P.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX, United States
Oidor-Chan V.H.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
Loeza-Alcocer E.:
Departamento de Fisiología, Biofísica y Neurociencias, Cinvestav, Zacatenco, Ciudad de México, Mexico
Department of Neurobiology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, United States
Pineda-Farias J.B.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
Department of Neurobiology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, United States
Velazquez-Lagunas I.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
Salinas-Abarca A.B.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
Hong E.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
Sánchez-Mendoza A.:
Departamento de Farmacología, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico
Delgado-Lezama R.:
Departamento de Fisiología, Biofísica y Neurociencias, Cinvestav, Zacatenco, Ciudad de México, Mexico
Price T.J.:
School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX, United States
Granados-Soto V.:
Neurobiology of Pain Laboratory, Departamento de Farmacobiología, Cinvestav, Sede Sur, Ciudad de México, Mexico
|